Today: 11 June 2026
Paymentus stock tumbles nearly 10% as fintech slides; oversold RSI flashes for PAY
2 January 2026
1 min read

Paymentus stock tumbles nearly 10% as fintech slides; oversold RSI flashes for PAY

NEW YORK, Jan 2, 2026, 2:07 PM ET — Regular session

  • Paymentus Holdings shares slid about 10% in afternoon trading after an early bounce faded.
  • A Nasdaq technical screen flagged PAY as “oversold,” with a key momentum gauge dipping below 30.
  • Investors are now looking ahead to the company’s next earnings update and whether the broader payments selloff deepens.

Paymentus Holdings, Inc. shares were down 9.7% at $28.53 in afternoon trading on Friday, after touching a session low of $28.53. The stock opened at $31.43, hit an intraday high of $31.63 and has traded about 703,000 shares, compared with a prior close of $31.59.

The slide matters because Paymentus, a bill-payment software provider, has traded like a sentiment gauge for investors’ appetite for growth-oriented payments names. A near-double-digit move in a single session can force portfolio managers and short-term traders to reassess positioning quickly.

The drop also lands as markets enter the early stretch of a new year, when investors often rotate exposure and reset risk budgets. In that environment, stocks that have relied on growth expectations can see sharper swings when risk appetite cools.

Broader markets were softer. The S&P 500-focused SPDR S&P 500 ETF was down about 0.3%, while the tech-heavy Invesco QQQ ETF slipped about 0.7%.

Paymentus was not alone among payments and fintech names. BILL Holdings fell about 7%, Toast dropped about 4.8% and Global Payments slid about 2.6% in the same session.

Technical traders also pointed to momentum signals. BNK Invest wrote on Nasdaq that Paymentus entered “oversold” territory, with its relative strength index (RSI) at 29.9 after shares traded as low as $28.89. RSI is a widely used momentum gauge; readings below 30 are often viewed as showing heavy selling pressure. Nasdaq

Paymentus sells cloud-based bill payment technology to billers and financial institutions, and says its platform is used by tens of millions of consumers and businesses in North America. The company says it serves more than 2,500 billers and financial institutions.

For investors, the question is whether Friday’s move is mostly a sector-wide risk-off trade or something more specific that emerges in coming disclosures. Paymentus has tended to trade on expectations for continued payment volume growth and operating leverage as it scales.

The next obvious checkpoint is earnings. Earnings calendars from TipRanks and Investing.com list Paymentus’ next report for Feb. 18, after the close, though schedules can change.

When results arrive, investors will be watching revenue growth, payment transaction volume, and profitability trends such as margins. Any update to forward guidance is likely to matter as much as the quarter itself in setting the tone for valuation-sensitive names.

Stock Market Today

  • Wall Street Gains on AI Stock Rally Amid Inflation and Middle East Tensions
    June 11, 2026, 11:16 AM EDT. Wall Street recovered some weekly losses Thursday as artificial intelligence (AI) stocks rebounded, led by chipmakers like Marvell Technology (+5.5%), Intel (+7.8%), and Applied Materials (+7.5%). The S&P 500 rose 0.5%, Dow Jones 0.7%, and Nasdaq 0.7%. Despite market gains, concerns about elevated AI valuations persist, while Oracle shares fell 11.1% after revealing plans to raise $40 billion to fund AI investments. Oil prices remained steady despite rising tensions in the Iran conflict, with Brent crude at $92.64 and U.S. crude at $90.29 per barrel. Meanwhile, wholesale inflation in the U.S. exceeded expectations in May, prompting the European Central Bank to raise interest rates, signaling global inflationary pressures.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal
Previous Story

Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal

Caterpillar stock jumps 4% as Wolfe lifts target to $670; investors brace for Jan. 9 jobs report
Next Story

Caterpillar stock jumps 4% as Wolfe lifts target to $670; investors brace for Jan. 9 jobs report

Go toTop